Company intelligence / Profile preview
Shanghai Jinmante Biotechnology Co., Ltd.
Shanghai, Shanghai, Chinajmt-bio.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Shanghai Jinmante Biotechnology has several products in various stages of development, with Narlumosbart (JMT-103) approved in China for Giant Cell Tumor of Bone in September 2023, and Becotatug (JMT-101) in Phase III trials for non-small cell lung cancer. The company is actively conducting clinical trials for multiple oncology indications.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Monoclonal antibodiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
CSPC ZhongQi Pharmaceutical TechnologyPeking University
Beyond the preview
Go deeper on Shanghai Jinmante Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Jinmante Biotechnology Co., Ltd..